Newsroom

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Harte Hanks, Inc. (NASDAQ: HHS) to Star Equity Holdings, Inc. Under the terms of the proposed transaction, Harte Hanks shareholders may elect to receive either (1) $5.00 in cash for each Harte Hanks share, or (2) 0.50 shares of Star Equity’s publicly traded 10% Series A Cumulative Perpetual Preferred Stock for each Harte Hanks share.Halper Sadeh encourages Harte Hanks shareholders to click here...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of GoPro, Inc. (NASDAQ: GPRO) to Starman Optical, Inc. for $1.14 per share, subject to potential adjustment based on GoPro’s net working capital at closing. Halper Sadeh encourages GoPro shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investig...

CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink® 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla. First responders rel...

WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA® plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi...

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer...

ニューヨーク--(BUSINESS WIRE)--（ビジネスワイヤ） -- ライフゾーン・メタルズ・リミテッド（NYSE：LZM）は、オリオン・リソース・パートナーズの創業者兼グループ最高経営責任者であるOskar Lewnowski氏が、タンザニアにおけるライフゾーン・メタルズの「カバンガ・ニッケル・プロジェクト」に関してブルームバーグテレビジョンのインタビューで述べた内容についてお知らせします。 インタビュー後にメディアや投資家から寄せられた問い合わせを受け、ライフゾーン・メタルズは、カバンガ・ニッケル・プロジェクトへの大規模な出資を巡るオリオン重要鉱物コンソーシアム（Orion CMC）との交渉がかなり進展していることを確認しました。 Orion CMCは、オリオン・リソース・パートナーズが米国国際開発金融公社（DFC）およびアブダビの政府系投資会社ADQと提携して立ち上げたグローバル投資プラットフォームです。 既に発表しているとおり、ライフゾーン・メタルズは、カバンガ・ニッケル・プロジェクトへの戦略的投資を確保するため、スタンダードチャータード銀行が主導する競争的プロセスを進...

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation Factor-15 (GDF-15) blockade with visugromab substantially enhanced the anti-tumor activity of the PD‑1 inhibitor nivolumab in the neoadjuvant treatment of patients with...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph....